Hantz Financial Services Inc. Acquires New Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Hantz Financial Services Inc. bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 3rd quarter, Holdings Channel reports. The institutional investor bought 161,772 shares of the biopharmaceutical company’s stock, valued at approximately $9,260,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HALO. Boston Trust Walden Corp purchased a new stake in shares of Halozyme Therapeutics in the second quarter valued at $23,211,000. Swedbank AB acquired a new stake in Halozyme Therapeutics in the 1st quarter worth about $13,927,000. Segall Bryant & Hamill LLC increased its stake in shares of Halozyme Therapeutics by 16.3% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock valued at $20,330,000 after acquiring an additional 49,856 shares during the last quarter. Creative Planning lifted its holdings in shares of Halozyme Therapeutics by 43.2% during the 2nd quarter. Creative Planning now owns 37,291 shares of the biopharmaceutical company’s stock worth $1,953,000 after acquiring an additional 11,249 shares during the period. Finally, Boston Partners boosted its position in shares of Halozyme Therapeutics by 14.1% in the first quarter. Boston Partners now owns 630,368 shares of the biopharmaceutical company’s stock worth $25,500,000 after acquiring an additional 77,976 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on HALO shares. Benchmark reaffirmed a “buy” rating and set a $60.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. JMP Securities increased their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st. Wells Fargo & Company cut Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their target price for the company from $58.00 to $62.00 in a report on Monday, October 7th. JPMorgan Chase & Co. downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their price objective for the stock from $52.00 to $57.00 in a report on Thursday, September 19th. Finally, Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $61.11.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $52.58, for a total transaction of $525,800.00. Following the completion of the sale, the chief executive officer now owns 676,744 shares of the company’s stock, valued at approximately $35,583,199.52. This trade represents a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 60,000 shares of company stock valued at $3,425,000 in the last three months. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Stock Performance

NASDAQ:HALO opened at $48.20 on Friday. Halozyme Therapeutics, Inc. has a 1-year low of $33.15 and a 1-year high of $65.53. The stock has a market cap of $6.13 billion, a P/E ratio of 15.96, a PEG ratio of 0.44 and a beta of 1.29. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The firm has a 50-day moving average of $53.28 and a two-hundred day moving average of $53.67.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.